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Aim: To set up a chromatographic strategy for the determination of log P for beyond Rule of 5 (bRo5)
drugs.Materials & methods: Capacity factors measured by reverse phase-HPLC. Balance of intermolecular
interactions governing systems assessed by partial least squares regression (PLSR) coupled with block rel-
evance anaysis (PLSR-BR) and multiblock PLSR (MBPLSR). Determination of virtual log P obtained through
conformational sampling. Results: log k′60 is highly correlatedwith log P for a dataset of 36 Ro5 compliant
compounds (R2 = 0.93, Q2 = 0.90). We refer to the value generated via this method as BRlogP. The balance
of intermolecular forces controlling BRlogP and log P are very similar. The ElogPs measured for the bRo5
dataset are significantly higher than corresponding BRlogP. Conclusion: The combination of BRlogP and
ElogP provides an experimental lipophilicity range for bRo5 compounds.
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The major role played by lipophilicity in drug discovery is widely known [1,2] and recently reviewed by Goetz
and Shalaeva [3], who illustrated the potential of lipophilicity in balancing potency and absorption, distribution,
metabolism, and excretion (ADME) properties from the point of view of the pharmaceutical industry. Lipophilicity
is commonly described as log D, where the distribution coefficient D is quantified by the concentration of all
species (unionized and ionized) of a compound at a given pH in two immiscible phases (commonly 1-octanol and
water/buffer) at equilibrium. Distribution coefficient (D) is replaced with partition coefficient (P) at any given pH
if only one species (typically neutral) is present.
HPLC is a widely used analytical technique that characterizes the physicochemical properties of compounds [4].
Chemicals are retained proportionally to their partition coefficient in the octanol/water system under the reverse
phase-HPLC (RP-HPLC) conditions on analytical columns packed with a solid phase made of long hydrocarbon
chains (e.g., C8 and C18) chemically bound onto silica. The RP-HPLC methods are therefore a reliable alternative
to other experimental log D/log P measurements (e.g., shake-flask) [5].
A number of research organizations have developed their own RP-HPLC methods for lipophilicity determi-
nations [3] and ElogP (ElogD) is the tool implemented, along with shake-flask, for Pfizer research programs [6,7].
Shortly, this method uses an octanol saturated mobile phase with methanol as organic modifier and an LC-ABZ
column as a stationary phase. The obtained log Kw data were calibrated with known log P (log D) values of a
training set and the obtained log P (log D) data are reported as ElogP (ElogD). The solvation analysis was performed
to verify the closeness in terms of balance of intermolecular interactions between the classical shake flask log P (log
D) values and ElogP (ElogD) [6,7].
The first aim of the present study is to test if a fast HPLC method based on a single log k′ value would yield
reliable log P values for neutral drug-like molecules. To do this, we tested two well-known columns (Supelcosil
LC-ABZ and XBridge™ Shield RP18, see methods) and mobile phases using acetonitrile as organic modifier. The
method was applied to a dataset of 36 known neutral Ro5 compliant compounds. It was validated for the balance
of intermolecular forces with two computational tools; partial least squares regression (PLSR) coupled with block
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relevance (BR) analysis and multiblock PLSR (MBPLSR). We refer to the value generated via this method as
BRlogP.
Recent investigations have highlighted that compounds residing just outside of traditional small molecule drug
space, in other words in the beyond rule of 5 (bRo5) space, allow modulation of difficult classes of targets [8].
The bRo5 drugs have a huge relevance in immunosuppression, treatment of infectious and viral diseases and in
oncology [9]. Reliable determination of physicochemical properties is required [10] for a successful design of bRo5
drugs, lipophilicity measurement being one of the most important parameters [3,9].
Lipophilicity accounts for molecular size and polarity of compounds in solution as well as for 3D conformational
changes [11] adopted by flexible molecules, which in turn depend on the polarity of the environment [12,13].
Therefore, it has to be demonstrated that methods optimized to measure log P for Ro5 molecules can be transferred
and successfully applied to bRo5 compounds since different systems (either biphasic or RP-HPLC), characterized
by different environments, can affect resulting lipophilicity values. Therefore, the second and main aim of the study
is to check the performances of BRlogP to assess the lipophilicity of bRo5 compounds. Since ElogP is one of the
most known lipophilicity indices implemented in drug discovery, it was selected as the method to compare against.
We selected nine bRo5 drugs and measured BRlogP and ElogP for in depth analyses. To investigate the role played
by flexibility, we also submitted the bRo5 drugs to a standard conformational sampling protocol and calculated the
lipophilicity of the conformers (i.e., virtual log P [14]). Experimental and computational lipophilicity were finally
compared.
Materials & methods
BRlogP
Deionized water and HPLC grade acetonitrile were used throughout. The mobile phases consisted of 20 mM
ammonium/acetate at pH 7.0 and acetonitrile from 60 to 80% v/v. Samples were dissolved in a 1:1 mixture of
buffer/acetonitrile in the concentration range of 50–100 ug/ml. The flow rate was 1 ml/min. The dead time, t0,
was determined by monitoring the baseline disturbance. The retention time (tR) was measured on a Supelcosil
LC-ABZ column (Supelco, 5 cm × 4.6 mm, 5 μm particle size, 120A˚ pore size) and XBridge™ Shield RP18
(Waters, 5 cm × 4.6 mm, 5 μm particle size, 130A˚ pore size). Isocratic log k′ (capacity factor k′ = [tR - t0]/t0)
values were measured.
ElogP
Deionized water and HPLC grade methanol were used throughout. The mobile phases consisted of 20 mMMOPS
buffer with 0.15% n-decylamine in octanol-1 saturated water at pH 7.4 and 0.25% octanol-1 in methanol at 60,
65 and 70% v/v. Samples were dissolved in methanol/water in the concentration range of 50–200 ug/ml. The
flow rate was 2 ml/min. Injections of pure methanol were used to determine the dead time t0. The retention time
(tR) was measured on a Supelcosil LC-ABZ column. Isocratic log k′ (capacity factor k′ = [tR - t0]/t0) values were
measured. The ELogP was determined by the published equation logPoct = 1.1267* log k′w +0.2075, where log
k′w is the log k′ extrapolated to 0% methanol, using a linear procedure [7].
PLSR & BR analysis
The PLSR models were built according to the following strategy. First, compounds were split in a training and
a test set and then the simplified molecular-input line-entry system codes of the compounds were submitted to
VolSurf+ (VS+, version 1.0.7, www.moldiscovery.com) using default settings and four probes (OH2, DRY, N1
and O probes that mimic, respectively, water, hydrophobic, hydrogen bond acceptor [HBA] and hydrogen bond
donor [HBD] properties of the environment). PCA and PLSR tools implemented in VS+ were used to obtain and
validate models.
The BR analysis was performed as described elsewhere [15–17]. Briefly, BR analysis organizes the VS+ descriptors
into six blocks (Size, Water, DRY, N1, O and Others) of straightforward significance detailed in Figure 1, panel B.
In a very simplistic way, BR analysis gives the relevance of each parameter (block) to the model.
Multiblock partial least squares regression
The multiblock PLSR as described by Westerhuis [18] was carried out using MVAPACK, implemented in Octave.
Briefly, MBPLSR generates a model of the response Y (log P and log k′60) as a linear function of the six blocks
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Figure 1. Relationship (Eq. 1) between log P and log k′60 measured with the X-Bridge column (training set: full
dots; test set: empty dots).
based on the VS+ descriptors (see above for blocks definition). To do that, descriptors (X) are first structured as
reported in the literature and then submitted to the modified PLSR algorithm [18].
The model with a number of latent variables that maximizes the leave-many-out cross validation coefficient
(Q2LMO) is chosen as the best model. Finally, the relative importance of each block is evaluated using the super
weights ws vector [19].
Molecular descriptors
All molecular descriptors were calculated with Dragon (software for molecular descriptor calculation) version
7.0.10, 2017, Kode srl, https://chm.kode-solutions.net, kindly provided by Todeschini.
Conformational sampling & virtual log P calculation
The simplified molecular-input line-entry system (SMILES) codes of the ten bRo5 drugs were obtained from
the DrugBank database (www.drugbank.ca/) and where used directly as input for OMEGA (OMEGA 3.0.1.2:
OpenEye Scientific Software, NM, USA. www.eyesopen.com, 2018). Default settings were applied. Virtual log P,
in other words the log P of any conformer, was calculated by projecting PLSR models obtained with VS+ (see
above) on the conformers generated by Omega.
Results & discussion
BRlogP
To set up a method to measure log P by RP-HPLC, the same dataset of 36 compounds used by Lombardo and
coworkers [6] was selected. It includes neutral, Ro5 compliant compounds, covering a log P range from -0.55 to
5.4. Three major points were evaluated: the stationary and mobile phases to be used, the chromatographic index
to be determined and the tools to be applied to validate the method, in other words how to compare the balance of
intermolecular forces governing the retention mechanism in the RP-HPLC system and the partitioning mechanism
in the reference system 1-octanol/water.
Among stationary phases, LC-ABZ provided excellent results and high correlations were found between log P
and chromatographic indexes for a wide range of structurally diverse compounds [6,20]. In this stationary phase,
the alkyl chains contain amide groups that electrostatically shield silanols from highly polar analytes. However,
the application of this type of stationary phases is still limited to the pH below eight because of instability in
alkaline media. A more recent RP-HPLC column (XBridge™ Shield RP18, from here on named XBridge) affords
a wider pH resistance (1–12) and bears the same alkyl chains as those in the LC-ABZ [21]. Overall both LC-ABZ
and X-Bridge deserve being considered as valuable stationary phases for the determination of a lipophilicity index.
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Acetonitrile was chosen since it was suggested to be the best organic modifier [19] and it is already applied in other
chromatographic systems recently developed in our laboratories (i.e., log k′80 PLRP-S) [22].
Two chromatographic indexes can be determined in principle: k′X% represents the capacity factor of the solute
at an X% organic solvent concentration, and Kw is the capacity factor extrapolated to a 0% concentration of the
organic solvent. Many studies tried to establish which descriptor gives the best correlation with lipophilicity, but
their review is beyond the scope of the paper. Here we decided to focus on log k′ since it is faster to obtain than
log Kw. Some years ago, we showed that for Lombardo’s dataset (n = 36) the balance of intermolecular forces
governing log k′60 determined on a LC-ABZ column using methanol as cosolvent was closer to log P than that
expressed by log Kw [16]. Therefore, in this study, we first focused on log k′60. However, since log k′80 is faster to
obtain (shorter retention times) and already implemented to determine lipophilicity in a chromatographic apolar
system [22], for the sake of comparison we also considered log k′80. Summing up, in this study we determined four
chromatographic indexes: log k′60 LC-ABZ, log k′80 LC-ABZ, log k′60 X-Bridge and log k′80 X-Bridge (Table 1).
Data analysis first revealed that the performances produced by the two columns are largely superimposable
(Supplementary Figure 1). Moreover, in agreement with a previous study [16], we verified that the relationship
between log P and log k′60 is stronger than the corresponding with log k′80 (Supplementary Figure 2). Therefore,
to set up a new lipophilicity index, we focused on log k′60 measured with the X-Bridge column which endowed
better pH stability than LC-ABZ.
The dataset was randomly split in training (24) and test (12) sets defined in Table 1. The relationship between
log P and log k′60 for the training set (the dataset) is reported in Figure 1 and the corresponding equation is below
(Eq. 1)
log . *log .
. ; . ; .
P k
R Q RLMO
2
Yscr
2
  
  
3 31 60 2 79
0 93 0 91 0 0422 (Eq. 1)
where R2 is coefficient of determination, Q2LMO is leave-many-out cross validation coefficient and R2Yscr is the
coefficient of determination of the corresponding scrambled models
In practice, once measured log k′60 with the X-Bridge column, we can calculate log P via Eq. 1. We termed this
log P as BRlogP since we used BR analysis for its mechanistic interpretation (see below).
Some of us recently published a study focusing on methods enabling the deconvolution of intermolecular
forces governing physicochemical descriptors [18]. The BR analysis is one of them and it was already successfully
applied to model chromatographic indexes [15,16,23]. Shortly, BR analysis provides a mechanistic ‘at a glance’ of
QSPR PLSR-based models using a ‘post processing’ supervised grouping of VS+ descriptors in blocks with a clear
physicochemical meaning. To avoid a postproduction process of the PLSR results, a modified PLSR algorithm
implementing blocks (MBPLSR) was also recently applied to interpret the logarithm of the retention coefficients
determined in an SDS MLC system (log KwSDS) [18]. Both computational approaches were applied in this study as
described below.
Log k′60 values were imported into VS+ as response variables (Y) and a relation between Y and the 82 VS+
molecular descriptors (X) was sought using the PLSR algorithm implemented in the software (see methods).
Statistically stable PLSR models were found (Table 2) and shown by the determination coefficients of the test set
(R2[test] in Table 2).
Graphical outputs of BR analysis are reported in Figure 2 along with the meaning and significance of the blocks.
Panel A and B (Figure 2) show the balance of intermolecular forces governing log P and log k′60 (Table 1). At first,
glance andwithout entering in the very details of BRplots interpretation, Figure 2A andB are almost superimposable;
the only slight difference being the size block (green) slightly smaller for the chromatographic descriptor. This finding
demonstrated that log P and BRlogP (calculated from log k′60) encode the same information.
The same data matrix were also submitted toMBPLSR and panel C and D in Figure 2 show the graphical results.
The same trend observed for PLSR-BR analysis is found for MBPLSR.
Lipophilicity of bRo5 drugs
As mentioned above the determination of lipophilicity for bRo5 compounds is a major need in modern drug
discovery. Since ElogP is a widely applied chromatographic descriptor of lipophilicity of industrial relevance, we
measured BRlogP and ElogP for nine neutral bRo5 drugs (Table 3, chemical structures in Supplementary Figure 3).
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Table 1. Chromatographic indexes discussed in the paper.
Compound tr/ts Log k′60 X-Bridge Log k′80 X-Bridge Log k′60 LC-ABZ Log k′80 LC-ABZ Log P
3,5-dichlorophenol Training 0.4 -0.03 0.45 0.02 3.68
3-bromoquinoline Training 0.27 -0.06 0.22 -0.12 3.03
3-chlorophenol Training 0.01 -0.27 0.07 -0.29 2.50
Acetaminophen Training -0.76 -0.8 -0.68 -0.8 0.51
Acetophenone Test -0.12 -0.36 -0.17 -0.48 1.58
Allopurinol Training -1.12 -1.12 -0.95 -0.98 -0.55
Antipyrine Test -0.69 -0.72 -0.57 -0.64 0.38
Bifonazole Test 0.42 -0.11 0.39 -0.16 4.77
Bromazepam Test -0.39 -0.52 -0.24 -0.51 1.65
Caffeine Training -0.91 -0.82 -0.72 -0.72 -0.07
Carbamazepine Test -0.34 -0.55 -0.27 -0.59 2.19
Chloramphenicol Training -0.4 -0.67 -0.41 -0.67 1.14
Clotrimazole Training 0.43 -0.08 0.37 -0.13 5.20
Dexamethasone Training -0.38 -0.55 -0.28 -0.54 1.83
Diazepam Test 0.12 -0.24 0.05 -0.31 2.79
Diethylstilbestrol Test 0.43 -0.08 0.39 -0.14 5.07
Estradiol Test 0.21 -0.13 0.33 -0.03 4.01
Fluconazole Training -0.83 -0.88 -0.66 -0.75 0.50
Griseofulvin Training -0.15 -0.43 -0.15 -0.54 2.18
Hydrocortisone Training -0.4 -0.55 -0.36 -0.54 1.55
Hydrocortisone-21-acetate Training -0.12 -0.42 -0.12 -0.48 2.19
Lorazepam Training -0.15 -0.46 -0.15 -0.44 2.51
Lormetazepam Training -0.04 -0.35 0.01 -0.42 2.72
Methylthioinosine Training -0.87 -0.95 -0.88 -0.91 0.09
Metronidazole Training -0.64 -0.76 -0.64 -0.7 -0.02
Naphtalene Training 0.43 0.01 0.38 -0.1 3.37
Nifedipine Test 0.08 -0.34 -0.07 -0.43 3.17
Nifuroxime Training -0.24 -0.52 -0.27 -0.59 1.28
Nitrofurazone Training -0.62 -0.8 -0.62 -0.8 0.23
Pentoxifylline Test -0.64 -0.67 -0.64 -0.79 0.29
Prednisolone Training -0.44 -0.56 -0.37 -0.57 1.60
Prednisone Test -0.48 -0.63 -0.45 -0.66 1.46
Quinoline Training -0.17 -0.36 -0.13 -0.36 2.03
Testosterone Test 0.08 -0.22 0.12 -0.12 3.29
Thiamphenicol Training -0.76 -0.81 -0.71 -0.82 -0.27
Tolnaftate Training 0.82 0.15 0.68 -0.02 5.40
Compounds belonging either to the training or to the test set are indicated. Log P data were taken from the paper by Lombardo et al. [6].
Table 2. Final models obtained using partial least squares regression and multiblock partial least squares regression.
Algorithm Descriptor N N training N test R2 Q2LMO LVs Slope Intercept R2(Test)
PLSR Log k′60 36 24 12 0.86 0.58 3 1.16 0.00 0.74
PLSR Log P 36 24 12 0.93 0.57 3 1.06 -0.36 0.70
MBPLSR Log k′60 36 24 12 0.86 0.51 3 1.10 0.06 0.50
MBPLSR Log P 36 24 12 0.90 0.62 3 1.05 -0.11 0.56
N = total number of compounds, N training = training set compounds, N test = test set compounds, R2 = coefficient of determination, Q2LMO = cross-validation coefficient leave-
many-out, in which about 30% of compounds are randomly excluded for prediction for 2000 iterations, LVs = number of latent variables, slope = slope of the linear regression obtained
by plotting experimental vs predicted data of the training set, intercept = intercept of the linear regression obtained by plotting experimental vs predicted data of the training set, R2
(test) = coefficient of determination for the test set.
LV: Latent variable; MBPLSR: Multiblock PLSR; PLSR: Partial least squares regression.
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Figure 2. Mechanistic interpretation of log P and log k′60. (A) log P (block relevance analysis), (B) log k′60 block relevance analysis), (C)
log P (multiblock PLSR), (D) log k′60 (multiblock PLSR) and (E) meaning and significance of the blocks.
Moreover, in Table 3 we also report AlogP, a calculated value of lipophilicity, recently included in the determination
of the lipophilicity permeability efficiency to replace experimental data [24]. Shortly, AlogP is a fragment-based 2D
octanol/water partition coefficient calculator [25] which is expected to provide good accuracy for large molecules
log P calculations. The relationship between BRlogP/ElogP and AlogP for the nine bRo5 drugs is poor (R2 about
0.5, Supplementary Figure 4) and confirms that caution should be used in replacing an experimental lipophilicity
value with a calculated one in the bRo5 chemical space.
Figure 3 shows the relationship between BRlogP and ElogP. For the traditional Ro5 compliant compounds, the
two methods show an excellent correlation (R2 = 0.93, slope about 1 and Y-intercept about 0). For bRo5 drugs,
although BRlogP and ElogP are still highly correlated (R2 = 0.96), the slope is higher than one (1.24) and the
Y-intercept higher than 0 (0.67). This finding shows that the two chromatographic systems provide the same log P
for small compounds but not for bRo5 drugs. This is particularly evident for lipophilic compounds.
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Table 3. bRo5 compounds: lipophilicity data.
BRlogP ElogP AlogP Exp log P range†
Atazanavir 3.0 4.7 5.3 1.68
Cyclosporine 5.8 8.5 5.6 2.69
Everolimus 4.9 6.7 6.0 1.84
Indinavir 1.6 3.8 3.2 2.24
Paclitaxel 3.2 4.4 3.1 1.24
Ritonavir 3.2 4.9 5.5 1.74
Tacrolimus 4.8 6.1 4.7 1.26
Telaprevir 3.5 4.4 3.4 0.94
Temsirolimus 4.8 6.9 5.8 2.06
†ElogP-BRlogP.
BRlogP and ElogP are experimental values whereas AlogP is computed using the Dragon software.
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Figure 3. Relationship between BRlogP and ElogP for the Ro5 compliant compounds (empty dots) and the bRo5
drugs (full dots).
The BRlogP and ElogP experimental conditions differ in the type of column (LC-ABZ vs X-Bridge), pH (7.0
vs 7.4), mobile phase composition (acetonitrile vs methanol and octanol) and nature of the chromatographic
index (log k′ vs log Kw). In the first part of the study, we verified that LC-ABZ and X-Bridge provided very similar
retention values and consequently the column type is not expected to impact retention. Since we are examining only
neutral compounds here, the differences in pH and buffer composition are expected to be not relevant. Therefore,
the major differences between the two methods are the mobile phase composition and the extrapolation process
required to obtain ElogP. We can therefore conclude that BRlogP and ElogP provide two diverse environments
with different polarity. This could impact the conformers’ population and thus log P value of bRo5 compounds.
Data suggest that ElogP seems to provide an environment in which compounds are forced to assume a more folded
and lipophilic conformation than under BRlogP conditions.
To investigate this finding further, we performed conformational sampling on the bRo5 compounds and
calculated log P for any conformer (i.e., virtual log P) using the second PLSR model (log P) reported in Table 1
(more details about the calculation of virtual log P and its relevance in drug discovery can be retrieved in the
literature [26,27]). The computed distribution of lipophilicity among conformers is displayed as a box and whisker
plot in Figure 4. Moreover, two conformers with low and high log P (data in Supplementary Table 1) are shown as
examples for indinavir and CsA (Figure 4). Experimental BRlogP and ElogP are also indicated in red and black,
respectively. The computed AlogP values are in green in Figure 4.
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Figure 4 shows that BRlogP (red bar) is in the 0–25th percentile of virtual log P except for ritonavir, tacrolimus
and temsirolimus. The ElogP (black bar) is often much higher than any virtual log P values. The AlogP (green bar)
varies with the considered compound and no clear trend can be found. Sometimes it is found within the 25–75th
percentiles (c.f. indinavir and tacrolimus), but often it is located either in the 0–25th or in 75–100th percentile.
The combination of BRlogP and ElogP provides an experimental range of log P (= ElogP - BRlogP in Table 3)
which spans from about one for telaprevir to about 2.7 for CsA. Notably, the experimental log P range is larger for
macrocyclic compounds (CsA, everolimus, paclitaxel, tacrolimus and temsirolimus) than for nonmacrocyclic drugs
(atazanavir, indinavir, ritonavir and telaprevir). Finally, the experimental log P range is not superimposable with
the virtual log P range. A lack of superposition between experimental and theoretical ranges is also found when
using a different method to calculate virtual log P (i.e., log P from MLP calculated with Vega software v. 3.1.1.42,
data in Supplementary Table 1). Work along these lines is in due course in our laboratories.
Overall Figure 4 supports that a single log P value often poorly represents the lipophilicity of conformationally
flexible bRo5 compounds, which is better described by an experimental lipophilicity range. In addition, the
lipophilicity range could be used to quantify the chameleonic properties of compounds in the bRo5 chemical space,
10.4155/fdd-2019-0002 Future Drug. Discov. (2019) future science group
Experimental lipophilicity for beyond rule of 5 compounds Research Article
where a chameleon is a molecule for which the closed form is preferred in apolar environments and the open form
in aqueous media [28]. This is a topic of huge relevance in modern drug discovery [29].
Conclusion
Wehave shown that BRlogP is a valuable and fast tool to experimentally access lipophilicity of neutral Ro5 compliant
compounds. Its combination with ElogP provides an experimental log P range that could be implemented in bRo5
drug discovery programs. The possibility of using different HPLC methods to measure ‘conformer-dependent’
experimental log P values is highlighted. Work is in progress to find a similar method to determine log D at
physiological pHs where most drugs are partially of fully ionized.
Future perspective
As recently reviewed in the literature [9,30], there is an increasing focus in the bRo5 chemical space. Notably in the
past 3 years, 21% of new oral drugs (12) do not comply with Lipinski’s Ro5. However, the understanding of the
rules that govern a successful design of oral bRo5 drugs is far from being achieved. A major issue concerns drug
metabolism and pharmacokinetic properties, sincemost bRo5 candidates show poor permeability, low solubility and
high metabolic clearance. Lipophilicity is a molecular property largely impacting the ADME profile of compounds,
and therefore there is the need to obtain lipophilicity descriptors for large and flexible structures. Since molecular
properties such as log P of bRo5 compounds strongly depend on their chameleonic properties (a chameleon is a
molecule for which the closed form is preferred in apolar environments and the open form in aqueous media), there
is no guarantee that experimental and computational protocols developed on Ro5 compliant structures properly
work on bRo5 compounds. In fact, the characteristics of the environment were generally poorly considered during
the development of methods in the Ro5 era. Therefore, we expect that drug discovery campaigns in the bRo5
chemical space in the next years will implement specific methodological solutions for the determination of ad hoc
physicochemical descriptors. The experimental lipophilicity range determined with ElogP and BRlogP is in line
with this scenario.
Summary points
• A fast chromatographic index to assess log P (BRlogP) based on the determination of a single reverse phase
high-performance liquid chromatography retention time is described and validated for Ro5 compliant
compounds.
• The applicability domain of BRlogP to bRo5 compounds is verified in relation with ElogP.
• The limits of simple (AlogP) and more complex (virtual log P) computed lipophilicity descriptors are highlighted.
• The combination of BRlogP and ElogP provides an experimental log P range, which could quantify the
chameleonic properties of bRo5 drugs.
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